Description: Santen Pharmaceutical Co., Ltd. researches and develops, produces, and markets pharmaceuticals and medical devices in Japan and internationally. It offers prescription pharmaceutical products for glaucoma and ocular hypertension, dry eyes, allergic conjunctivitis, severe keratitis with dry eyes, vernal keratoconjunctivitis, uveitis, wet age-related macular degeneration, and myopia; and over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
Home Page: www.santen.com
Grand Front Osaka Tower A
Osaka,
530-8552
Japan
Phone:
81 6 7664 8621
Officers
| Name | Title |
|---|---|
| Mr. Takeshi Ito | Pres, CEO & Representative Director |
| Mr. Kazuo Koshiji | Chief Financial Officer & Chief Risk Officer |
| Mr. Minori Hara | Chief Digital & Information Officer |
| Ms. Kaori Itagaki | Gen. Mang. of Investor Relations Group |
| Ms. Mika Masunari | Gen. Counsel & Chief Compliance Officer |
| Ms. Nobuko Kato | Chief Communications Officer |
| Mr. Satoshi Suzuki | Sr. Corp. Officer & Head of Corp. Devel. Division |
| Mr. Shinichi Teramachi | Corp. Officer, Head of Sales Department & Japan Sales and Marketing Division |
| Mr. Ippei Kurihara | Corp. Officer and Head of Marketing Department, Japan Bus., Japan Sales & Marketing Division |
| Mr. Kenji Morishima | Corp. Officer & Head of China Product Devel. Department |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 12.9534 |
|---|---|
| Trailing PE: | 16.0198 |
| Price-to-Book MRQ: | 1.3935 |
| Price-to-Sales TTM: | 0.0118 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 4315 |